• Skip to main content

Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

N(1)-Methylnicotinamide

Protective Effects of N(1)-Methylnicotinamide (MNAM) Against Hearing Loss via Moderate Overexpression of Sirtuin 1 Protein

April 6, 2021

CATEGORY:
Research

SCREENSHOT:
Protective Effects of N(1)-Methylnicotinamide Against High-Fat Diet- and Age-Induced Hearing Loss via Moderate Overexpression of Sirtuin 1 Protein

TITLE:
Protective Effects of N(1)-Methylnicotinamide Against High-Fat Diet- and Age-Induced Hearing Loss via Moderate Overexpression of Sirtuin 1 Protein

CONTENT:
Front Cell Neurosci. 2021 Apr 6;15:634868. doi: 10.3389/fncel.2021.634868. eCollection 2021.

ABSTRACT

Age-related hearing loss (ARHL) is the most common form of hearing loss and the predominant neurodegenerative disease associated with aging. Sirtuin 1 (SIRT1) is associated with the most complex physiological processes, including metabolism, cancer onset, and aging. SIRT1 protein levels are enhanced by the conversion of nicotinamide to N1 -methylnicotinamide (MNAM), independent of its mRNA levels. Moreover, MNAM has implications in increased longevity achieved through its mitohormetic effects. Nicotinamide N-methyltransferase (Nnmt) is an enzyme involved in MNAM metabolism, and its level increases under caloric restriction (CR) conditions. The CR condition has implications in delaying ARHL onset. In this study, we aimed to determine the relationship between diet, hearing function, SIRT1 and SIRT3 expression levels in the inner ear, and cochlear morphology. Mice fed with a high-fat diet (HFD), HFD + 1% MNAM, and low-fat diet (LFD) were monitored for age-related auditory-evoked brainstem responses, and changes in cochlear histology, metabolism, and protein and mRNA expressions were analyzed. Our results revealed that the HFD- and aging-mediated downregulated expression of SIRT1 and SIRT3 promoted hearing loss that was obfuscated by MNAM supplementation-induced upregulated expression of cochlear SIRT1 and SIRT3. Thus, our results suggest that MNAM can be used as a therapeutic agent for preventing ARHL.

PMID:33889076 | PMC:PMC8055820 | DOI:10.3389/fncel.2021.634868

SOURCE:
Frontiers in cellular neuroscience

PUBLISHER:

PMID:
pubmed:33889076

ID:
0b58ea4968e09ff10f4e1238c494f316pubmed:33889076

DOI:
10.3389/fncel.2021.634868

DATE – PUBLISHED:
Fri, 23 Apr 2021 06:00:00 -0400

DATE – DOI:
2021-04-06T04:35:29Z

DATE – ADDED:
04/23/21 01:45PM

LINK – PUBMED:
https://pubmed.ncbi.nlm.nih.gov/33889076/

LINK – DOI:
https://doi.org/10.3389/fncel.2021.634868

LINK – PUBLISHER:
https://www.frontiersin.org/articles/10.3389/fncel.2021.634868/full?utm_source=hearinglosstreatmentreport.com

IMAGE:

REFERENCE:
Hearing Loss Treatment Report, Urgent Research, 2021-04-23T17:45:47+00:00, https://www.hearinglosstreatmentreport.com.

Powered by Urgent Research

Copyright © 2025 Urgent Research